Natural cocoa consumption in sickle cell disease

Effect of natural cocoa powder consumption on blood lipids, inflammatory and metabolic biomarkers in sickle cell patients at the Ghana Institute of Clinical Genetics (GICG), Korle Bu Teaching Hospital

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202401734091130

Enrollment

150

Registered

2024-01-09

Start date

2024-02-05

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Diseases

Interventions

Cocoa group

Control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants who are willing to be followed for the 12-week trial period will be included in the study. Sickle cell patients who are not on any lipid lowering drugs will be included in the RCT.

Exclusion criteria

Exclusion criteria: Participants on lipid lowering medication prior to phase II will be excluded. Further, participants with complications (liver/renal conditions) will be excluded due to the high potassium content of cocoa

Design outcomes

Primary

Measure	Time frame
The main endpoint will be assessed by the mean changes in lipid profile (HDL-cholesterol and triglycerides	—

Secondary

Measure	Time frame
The clinically relevant measures will be BMI, blood pressure, waist circumference, hip circumference, waist-to-hip ratio, fasting blood glucose level, C-reactive protein levels, Interleukin-6, TNF-alpha and oxidative stress biomarkers (SOD, CAT). The differences will be compared between intervention and control groups	—

Countries

Ghana

Contacts

Public ContactFrederick Addai

Professor University of Ghana

professoraddai194@gmail.com+233244643209

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026